Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 1/2 2

Status

Completed 5

Sponsor Class

OTHER 11INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 3Dermatologic 2Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Breast 1

Conditions

Medulloblastoma 2Carcinoma, Basal Cell 2Stomach Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × sonidegib × Clear all
NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
120 enrolled
BreastCNSGastrointestinal

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

NCT01769768 2020-12-19

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Novartis

Phase 1 Completed
114 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Novartis

Phase 1 Completed
11 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡